Soleno Therapeutics (SLNO) EBIT Margin (2015 - 2026)
Soleno Therapeutics (SLNO) reported EBIT Margin of 33.06% for Q1 2026, down 23.37% on a QoQ basis from 43.15% in Q4 2025.
Soleno Therapeutics (SLNO) has 5 years of EBIT Margin data on file, last reported at 33.06% in Q1 2026.
- Quarterly EBIT Margin changed N/A year-over-year to 33.06% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 30.33% (changed N/A YoY) and the FY2025 annual result came in at 4.94%, changed N/A from the prior year.
- EBIT Margin fell to 33.06% in Q1 2026 per SLNO's latest filing, from 43.15% in the prior quarter.
- Across five years, EBIT Margin topped out at 43.15% in Q4 2025 and bottomed at 19.98% in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 17.83% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 23.02% |
| 10 | Soleno Therapeutics | 2.76 Bn | 2.51 Bn | 93.41 Mn | 33.06% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 33.06% |
| Dec 31, 2025 | 43.15% |
| Sep 30, 2025 | 33.48% |
| Jun 30, 2025 | -19.98% |
| Jun 30, 2017 | -296,800.00% |
| Mar 31, 2017 | -518.11% |
| Dec 31, 2016 | -126.35% |
| Sep 30, 2016 | -598.18% |
| Jun 30, 2016 | -114,750.00% |
| Mar 31, 2016 | -953.69% |
| Dec 31, 2015 | -4,744.17% |
| Sep 30, 2015 | -11,788.89% |
| Jun 30, 2015 | -3,138.14% |
| Mar 31, 2015 | -11,027.27% |